Fri 15'th Jun 2018
Catabasis Pharmaceuticals Stock Analysis
Technical stock analysis for Fri 15'th Jun 2018
Catabasis Pharmaceuticals fell by -2.90% in the last day from $1.38 to $1.34 The price has fallen in 7 of the last 10 days and is down by -22.54% for this period. Volume has increased in the last day by 45 262 shares, but on falling prices. This may be an early warning and the risk will be increased slightly for the next couple of days. In total, 252 673 shares bought and sold for approximately $0.00.
|Shorts||3.66% ( 2018-05-31 )|
Catabasis Pharmaceuticals has broken the wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($1.37) are considered to be a "second chance" to get out. According to the fan-theory $1.08 will represent the new bottom line of the next trend, but it is far too early to say this for certain.
There are few to none technical positive signals at the moment. Catabasis Pharmaceuticals holds sales signals from both short- and long-term moving averages. In addition, there is a general sales signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up there will be some resistance from the lines at $1.42 and $1.59. A break-up above any of these levels will issue buy signals. A sales signal was issued from a pivot top point on Thursday May 31, 2018, which indicates further falls until a new bottom pivot has been found. Catabasis Pharmaceuticals gained volume on the last day, but on falling prices. In technical terms this is called divergence and may be an early warning. In some cases, increasing volume on falling prices may be considered positive, but that is mainly in typical "sell-off's".
Relative Strength Index (RSI)
RSI14 is 30 and the stock is currently not being overbought or oversold
Support & Resistance
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.08 between high and low, or 6.06%. For the last week, the stock has had a daily average volatility of 6.28%.
Our recommended stoploss: We hold a sell evaluation for this stock. No stop-loss set.
Very Low Low Medium High Very High
Catabasis Pharmaceuticals holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our recommendation for this stock since last evaluation from a Sell Candidate to a Strong Sell Candidate.
Trade CATB CFDs with Plus500
Your capital is at risk.
Important: Plus500 doesn't offer signals and it is a CFD service.
Plus500UK Ltd is authorised and regulated by the Financial Conduct Authority (FRN 509909).
Access these features
Auto portfolios gaining up to 30%
Top 5 Candidates in all Lists
Ultimate List Builder